Abstract-The structure-activity relationship (SAR) of the end pentyl chain in anandamide (AEA) has been established to be very similar to that of D
Introduction
During the last few decades there has been a surge of interest in cannabinoid pharmacology [1] [2] [3] [4] [5] driven by the identification of G-protein coupled cannabinoid receptors. 6, 7 The CB1 receptor is located both inside and outside the CNS, and the CB2 receptor is located mainly in the periphery. The first potent CB1 receptor antagonist SR141716A 8 was reported by Sanofi, and they also reported the CB2 selective receptor antagonist SR144528. 9 Anandamide (AEA) was identified as the endogenous ligand for the CB1 receptor and another key endogenous ligand which has been identified is 2-arachidonyl-glycerol (2-Ara-Gl), which activates both CB1 and CB2 receptors. Both AEA and 2-Ara-Gl are present together with a family of related fatty acid glycerol esters and the potency of 2-Ara-Gl was found to be improved in the presence of the related 2-acyl-glycerols. This effect has been termed the 'entourage effect' which probably represents a pathway for regulation of endogenous cannabinoid activity. 10 Mechoulam's group isolated another endogenous ligand 'noladin ether' (2-arachidonylglyceryl ether) from porcine brain. 11 It binds to CB1 receptors and very weakly to CB2 receptors. The pharmacological activities of D 9 -tetrahydrocannabinol (D 9 -THC) and the endogenous ligand AEA have some key differences. [12] [13] [14] [15] For example, the onset of action of AEA is much faster and the duration of action is much shorter when compared with D 9 -THC. This is due to the enzymatic hydrolysis of the amide bond in AEA and the enzyme involved in the metabolic degradation of AEA, 'fatty acid amide hydrolase' (FAAH).
In order to improve the metabolic stability of AEA, several analogs have been synthesized which have greater binding affinities than AEA. Makriyannis and coworkers incorporated a methyl in the amide head group which dramatically improved the metabolic stability of AEA, [16] [17] [18] while our group improved the metabolic stability by introduction of substituents on the carbon in the 2-position of the arachidonic acid part of AEA. [19] [20] [21] Our ongoing program on the SAR of classical THC's has revealed that the alkyl side chain has a vital effect on pharmacological activity. [22] [23] [24] [25] It has been well established by several groups, including ours, that the SAR of the end pentyl chain in anandamide (AEA) is often similar to that of the THC side chain. Branching of the side chain in THC's results in a dramatic increase in potency and efficacy, whereas this modification in the AEA series has produced only a moderate increase in potency. 26, 27 It is also well known that AEA activates CB1 receptors and also acts as an agonist at vanilloid VR1 receptors, whereas D 9 -THC activates both CB1 and CB2 receptors and acts as a partial agonist. Keeping these differences in mind we designed and synthesized hybrids of THC/AEA which we expect will provide ligands with novel pharmacological properties and will further our understanding of the role of the endocannabinoid system. We had previously incorporated the DMH (dimethylheptyl) side chain of THC into the AEA template, and to extend this approach we designed hybrid structures that incorporated the aromatic ring of THC-DMH and used the oxygen of the phenol/pyran ring of THC to include a part of the AEA moiety as an ether linkage. We designed and developed novel THC/AEA hybrid ligands (1) (2) (3) (4) (5) (6) (7) (8) (Fig. 1 ) that incorporate conformational restraint in the AEA part, and the synthesis and SAR results are described in this paper.
Chemistry
Our general synthetic strategy is based on the introduction of the AEA moiety in the targets by coupling of appropriately substituted phenols with the key intermediate 11-methanesulfonyloxy-undeca-5,8-dienoic methyl ester 16 (Scheme 1).
11-Methanesulfonyloxy-undeca-5,8-dienoic methyl ester
16 has been efficiently synthesized in our labs starting from homopropargyl alcohol 9, which was converted into its silyl ether 10 by treatment with t-BDPSiCl, imidazole. Treatment of 10 with formaldehyde in the presence of CuCl as catalyst gave the alcohol 11.
28
Bromination gave the propargyl bromide 12, which was then coupled with methyl hex-5-ynoate in the presence of CuI as catalyst to provide the diynoic acid methyl ester 13. 29, 30 Partial reduction of the diyne over 'nickel boride' catalyst provided the diene 14.
31 Deprotection of the silyl ether, followed by treatment of the alcohol 15 with MsCl, Et 3 N gave the desired mesylate 16 in 26% overall yield. 3-(2-Methyloctan-2-yl)phenol 25 which is required for the synthesis of hybrid 1 was synthesized starting from 3-methoxy benzoic acid (Scheme 2). The acid was converted into its corresponding Weinreb amide 19 which on treatment with hexyl magnesium bromide afforded the ketone 21.
32 Introduction of the dimethyl group was accomplished by treatment of ketone 21 with TiCl 4 , Me 2 Zn to give 23, which on demethylation with BBr 3 gave the phenol derivative 25. A similar sequence was used for the synthesis of the 4-(2-methyloctan-2-yl)phenol 26 starting from 4-methoxybenzoic acid 18. Condensation of the mesylate 16 with the phenols 25 and 26 in the presence of potassium hydroxide gave the desired ester precursors 27 and 28 for the target compounds 1 and 2, respectively. Hydrolysis of the ester hybrid 27 with lithium hydroxide provided the acid which was then converted to the corresponding acid chloride by treatment with oxalyl chloride and coupled with (R)-2-aminopropanol to give the target compound 1 in 89%. The synthesis of target 2 was accomplished using ester precursor 28 and following the same strategy as in the synthesis of hybrid 1. For the synthesis of hybrid target 3 (Scheme 3), the alcohol 15 was converted to the iodide 32 using triphenylphosphine and iodine. The iodide 32 was converted into the corresponding phosphonium iodide 33 by refluxing with triphenylposphine. Treatment of the phosphonium iodide 33 with NaHMDS converted it into the ylide which was then reacted with the aldehyde 31 in a Wittig reaction to afford the desired hybrid ester 34. The ester 34 was treated with (R)-2-aminopropanol in the presence of a catalytic amount of sodium cyanide to provide the target compound 3. The synthesis of Bromo compound 43 was synthesized by bromination of 41 with CBr 4 , Oct 3 P. Treatment of the bromide 43 with NaCN gave the hybrid ester 44. Target compound 4 was synthesized by treatment of 40 with (R)-2-aminopropanol in the presence of catalytic amount of NaCN followed by deprotection of the silyl protecting group with TBAF. The ester hybrids 43 and 44 were hydrolyzed to the corresponding acids and coupled with (R)-2-aminopropanol under the mixed anhydride condition using ClCOOEt to give the target compounds 5 and 7, respectively. Hydrolysis of the ester hybrid 42 to the corresponding acid and coupling with (R)-2-aminopropanol under the acid chloride condition using oxalyl chloride afforded the target compound 6. The synthesis of target compound 8 (Scheme 6) involved using synthon 45 which has been previously synthesized and reported by us. 29 Coupling of phenol 25 (Scheme 2) with the mesylate of alcohol 45 gave the desired ester 46 (Scheme 6). The ester hybrid 46 was hydrolyzed to the corresponding acid 47 and coupled with (R)-2-aminopropanol under the mixed anhydride condition using ClCOOEt to provide the target compound 8.
In summary we have developed a facile and convergent route for the synthesis of the hybrid analogs via the key intermediate 16.
Results and discussion
The hybrid 1 (O-2220) ( Table 1 ) was found to have good binding affinity to CB1 receptors (K i = 8.5 nM). Comparison of the results obtained with the hybrids revealed that the orientation of the side chain in hybrid 1 was important, and it is interesting to note that in 1 the orientation of the side chain to the phenolic oxygen is the same as in THC. When the orientation was changed to the C4-position as in 2 (O-2294) (CB1 K i = 195 ± 39), the binding affinity decreased 23-fold and activity in the tetrad tests was absent. The synthesis of the hybrid with an ether linkage at the C-2 position was attempted. However, our initial attempts were not successful due to the steric hinderance of the adjacent dimethylheptyl group. Hence, the hybrid 3 (O-2243) was synthesized in which we have a double bond in place of the ether linker. Hybrid 3 (O-2243) (CB1 K i = 86 ± 8.7) shows moderate binding affinity for CB1 receptors and moderate potency in two of the tetrad tests. In order to observe the effect of the change in length of the unsaturated backbone, we synthesized 8 (O-2655) (CB1 K i = 131 ± 14 nM). The introduction of the extra double bond was, however, found to be detrimental to the CB1 receptor binding affinity and in vivo activity.
To further explore the SAR of compound 1, several analogs were synthesized ( Fig. 1 ) with varying functional groups at the terminal end of the chain ( Table 1 ). The SAR points out that the presence of a hydroxyl group on the terminal carbon of the chain (O-2760) decreased binding affinity to the CB1 receptors but slightly increased selectivity to CB2 receptors. In the tetrad tests, the potency in depressing spontaneous activity and rectal temperature was increased 3-fold whereas the potency in producing analgesia (TF) and relative immobility (RI) was increased 14-fold. The azido substituent (O-2781) on the other hand has no effect on the binding affinity but showed increased potency in the tetrad tests. However, the bromo (O-2874) and the cyano (O-2852) substituents produced an increase both in the binding affinity and potency. The latter results are consistent with our previous work that showed increases in affinity and potency through bromo and cyano substitutions to the terminal end of the side chain of D 8 -THC. 34, 35 Our group has previously reported good AEA and D 9 -THC overlays (Thomas's model), which could predict by QSAR the potencies of various AEA analogs with a reasonable degree of accuracy. 36 We had found that a looped conformation of these AEA analogs is energetically favorable and that a structural correlation between this low energy conformation and the classical cannabinoids can be obtained with the superposition of (1) the oxygen of the carboxamide with the pyran oxygen in D 9 -THC, (2) the hydroxyl group of the ethanol with the phenolic hydroxyl group of D 9 -THC, (3) the five terminal carbons and the pentyl side chain of D 9 -THC, and (4) the polyolefin loop overlaying with the cannabinoid tricyclic ring. Our studies further showed that, when overlayed in this fashion, the potencies of AEA analogs are predictable by QSAR. The ability to incorporate the pharmacological potency of these AEA analogs into the cannabinoid pharmacophore model is also shown to support the relevance of this model. Preliminary molecular modeling studies of the hybrid 1 with D 9 -THC, was carried out in collaboration with Dr. Brian Thomas. An initial overlay between the structures of O-2220 and D 9 -THC was obtained (see (Fig. 3 ). The conformations obtained for O-2220 were similar to those determined by Barnett-Norris et al. 37 using the method of conformational memories (CM) to study the conformations available to a series of ethanolamide fatty acid acyl chain congeners. These studies also suggested that anandamide and its congeners adopt tightly curved U/J-shaped conformations to interact with the TMH 2-3-7 region of CB1. We plan to develop a pharmacophore for our hybrid AEA analogs and subsequently we will use the model's predictive ability to design more compounds.
In summary, these analogs showed an increase in binding affinity and improvement in the pharmacological activity that is very similar to the results obtained with THC side chain modified analogs.
Conclusion
The high receptor affinity and pharmacological potency of O-2220 provides further insight into the structural commonalities of THC and AEA that are required for biological activity. Incorporation of additional structural constraints in AEA will be necessary to establish its optimal conformation. However, the hybrids described herein illustrate the potential for developing new templates for cannabinoid receptor agonists and antagonists.
Experimental

General
All reagents were of commercial quality, reagent grade, and used without further purification. Anhydrous solvents were purchased from Aldrich and used without further purification. All reactions were carried out under N 2 atmosphere. Organic solutions were dried with Binding affinity results are presented as K i (nM); mice were injected iv with each analog and tested for suppression of spontaneous activity (SA), production of antinociception in the tail-flick procedure (TF), change in rectal temperature (RT) and production of ring immobility (RI). For compounds that produced dose-dependent effects, the results are presented as ED 50 s (lmol/kg). Approximate ED 50 s (indicated by $) are given when the highest dose tested produced half of the theoretical maximum response (e.g., temperature drop of À3°C). When dose-dependence was not obtained and the maximum effect did not approach the theoretical maximum for the test, magnitude of maximal effect was indicated along with the dose (mg/kg) at which it occurred (e.g., À0.9 at 30 indicates À0.9°C drop in body temperature at 30 mg/kg). Doses higher than 30 mg/kg were not tested. Superscript numbers in table indicate reference numbers for previously reported data.
sodium sulfate.
1 H NMR spectra were recorded on a JEOL Eclipse 300 MHz spectrophotometer using CDCl 3 as the solvent with tetramethylsilane as an internal standard. MS data were obtained on an Agilent 1100 LC/ MSD system. Thin-layer chromatography (TLC) was carried out on Baker Si 250F plates and was developed upon treatment with phosphomolybdic acid (PMA). Flash column chromatography was carried out on EM Science silica gel 60. Elemental analyses were performed by Atlantic Microlab, Inc., Atlanta, GA, and were found to be within ±0.4% of calculated values for the elements shown, unless otherwise noted.
tert-Butyl-but-3-ynyloxy-diphenylsilane (10)
To a stirred solution of 3-butyn-1-ol (5.0 g, 0.071 mol) in dry DMF (150 mL) at 0°C, was added imidazole (9.7 g, 0.14 mol) and tert-butyldiphenylsilyl chloride (19.5 g, 0.072 mol) and the resulting solution was stirred overnight. On completion, the reaction was diluted with water followed by extraction with EtOAc (4 · 500 mL). The organic extracts were combined, washed with brine, dried and concentrated in vacuo. The residue was chromatographed on silica, eluting with 1% EtOAc-hexanes to afford 19.6 g of 10 as a oil in 90% yield. 1 
Cuprous chloride (1.25 g, 0.0125 mol) was dissolved in 12% aqueous HCl (20 mL) to give a brown solution which was cooled to 0°C. To this stirred solution, 40% KOH solution (20 mL) was added dropwise over the course of an hour precipitating an orange solid. This solid was filtered with suction and washed well with water. The moist solid was subsequently added to a suspension of 10 (17.8 g, 0.058 mol), CaCO 3 (0.062 g, 0.0006 mol), H 2 O (1.25 mL) and 37% aq HCHO (6.2 mL) and the suspension heated at 110°C. The reaction was monitored by TLC for 5 days, cooled to room temperature, diluted with EtOAc (800 mL), washed with water and brine. The organic extracts were dried and concentrated in vacuo to yield a brown residue which was chromatographed on silica, eluting with 20% EtOAc-hexanes to give 15.5 g of 11 in 79% yield as a colorless oil.
1 H NMR d 1.05 (s, 9H), 2.48 (tt, 2H, J = 2.2, 7.14 Hz), 3.77 (t, 2H, J = 7.14 Hz), 4.19 (m, 2H), 7.35-7.45 (m, 6H), 7.65-7.7 (m, 4H).
5-(Bromopent-3-ynyloxy)-tert-butyl-diphenylsilane (12)
To a stirred solution of 11 (14.6 g, 0.043 mol) in dry ether (150 mL) at 0°C, was added CBr 4 (43.1 g, 0.13 mol) followed by dropwise addition of trioctyl phosphine (57.9 mL, 0.13 mol). The reaction was allowed to warm to room temperature and progress of the reaction was monitored by TLC. On completion the solvent was removed in vacuo and the residue subjected to column chromatography. On elution with 20% EtOAc-hexanes 15 g of 12 was obtained in 86% yield as yellow oil. 1 To a stirred solution of Ni(OAc) 2 (10.9 g, 0.044 mol) in EtOH (500 mL) saturated with H 2 (g), was added NaBH 4 (1.66 g, 0.044 mol) in portions and the resulting solution saturated with H 2 . To this was added ethylenediamine (3.71 mL, 0.055 mol) followed by a solution of 13 (10 g, 0.022 mol) in EtOH (50 mL), quickly maintaining the H 2 atmosphere after each addition. The reaction progress was monitored by TLC and on completion in 1 h was quenched with Et 2 O (200 mL). The reaction solution was then filtered through Celite pad under suction and the filtrate concentrated in vacuo. The residue was filtered through a small pad of silica to give 8. 
11-Hydroxyundeca-5,8-dienoic methyl ester (15)
To a solution of 14 (5.9 g, 0.013 mol), glacial AcOH (7.6 mL, 0.13 mol) in dry THF (70 mL), Bu 4 NF (1 M in THF, 122.7 mL, 0.13 mol) was added dropwise and reaction was stirred at room temperature. The reaction was monitored by TLC and on completion the solvent was removed in vacuo. The oily residue obtained was extracted into ether, washed with water and brine, dried, concentrated and subjected to chromatographic purification on a silica column. 2.5 g of 15 was obtained on elution with 20% EtOAc-hexanes in 91% yield as a colorless oil. 1 
N,3-Dimethoxy-N-methylbenzamide (19)
To a solution of 3-methoxybenzoic acid (10 g, 0.065 mol) in CH 2 Cl 2 (70 mL) stirred at 0°C was added DMF (0.8 mL) followed by oxalyl chloride (11.4 mL, 0.131 mol) dropwise. The reaction mixture was stirred and after 3-4 h was cannulated into addition funnel and added dropwise to a stirred solution of N,O-dimethylhydroxylamine hydrochloride (63.4 g, 0.65 mol) and Et 3 N (95.6 mL, 0.65 mol) in CH 2 Cl 2 (170 mL). The white heterogeneous mixture was left to stir vigorously at room temperature overnight. Water (200 mL) was added to the mixture followed by extraction with CH 2 Cl 2 . The combined organic extracts were washed with brine, dried and concentrated in vacuo. The residue was purified by column chromatography, eluting with 30% EtOAc-hexanes to give 38. 
1-(3-Methoxyphenyl)heptan-1-one (21)
To a solution of 19 (9.5 g, 0.048 mol) in THF (40 mL) was added dropwise a solution of hexylmagnesium bromide (2.0 M in ether, 26.4 mL, 0.0528 mol) and the reaction solution allowed to reflux for 6 h. After cooling to room temperature, the reaction was quenched with saturated NH 4 Cl solution followed by extraction with EtOAc (4 · 100 mL). The organic extracts were combined, washed with brine, dried and concentrated in vacuo. The residue was purified by column chromatography, eluting with 25% EtOAc-hexanes to afford 6.5 g of ketone 21 as a colorless oil in 61% yield.
1 H NMR d 0.90 (t, 3H, J = 6.87 Hz), 1.28-1.4 (m, 6H), 1.67-1.78 (quint., 2H, J = 7.14 Hz), 2.95 (t, 2H, J = 7.41 Hz), 3.85 (s, 3H), 7.08-7.12 (m, 1H), 7.36 (t, 1H, J = 7.8 Hz), 7.48-7.56 (m, 2H).
1-(4-Methoxyphenyl)heptan-1-one (22)
This was prepared from 20 in 89% yield by similar procedure as described for 21.
1 H NMR d 0.90 (t, 3H, J = 6.9 Hz), 1.23-1.43 (m, 6H), 1.67-1.76 (quint., 2H, J = 7.14 Hz), 2.91 (t, 2H, J = 7.14 Hz), 3.87 (s, 3H), 6.93 (d, 2H, J = 9.06 Hz), 7.94 (d, 2H, J = 9.06 Hz).
1-(1,1-Dimethylheptyl)-3-methoxybenzene (23)
A 1 M solution of TiCl 4 in CH 2 Cl 2 (30.4 mL, 0.27 mol) was added to CH 2 Cl 2 (125 mL) placed in a threenecked RB flask, fitted with an addition funnel and maintaining the temperature at À50°C under a steady stream of N 2 . This was followed by addition of (CH 3 ) 2 Zn (13.5 mL, 0.27 mol) via the addition funnel as quickly as possible while maintaining the temperature. The orange-brown solution obtained was stirred vigorously at À50°C for one hour after which a solution of 21 (10 g, 0.045 mol) in dry CH 2 Cl 2 (50 mL) was added dropwise. The reaction solution was allowed to stir for 2 h at À50°C, then allowed to reach À10°C before quenching by addition of ice-cold saturated NH 4 Cl solution dropwise. The aqueous layer was then extracted with CH 2 Cl 2 (5 · 200 mL), the organic extracts washed with brine, dried and concentrated in vacuo. The residue was purified by column chromatography, eluting with 1% EtOAc-hexanes to afford 10.2 g of 23 in 95% yield as a colorless oil. 1 
3-(1,1-Dimethylheptyl)phenol 25
To a solution of BBr 3 (1.0 M in CH 2 Cl 2 , 33.3 mL, 0.033 mol) cooled to 0°C was added a solution of 23 (6.9 g, 0.025 mol) in CH 2 Cl 2 (100 mL) dropwise. The reaction was allowed to stir overnight at room temperature. The reaction solution was cooled to 0°C and water (50 mL) was added dropwise. The aqueous layer was then extracted with EtOAc, the organic extracts combined, dried and concentrated in vacuo. The residue obtained was chromatographed on silica eluting with 3% EtOAc-hexanes to give 4 g of 25 as a viscous oil in 83% yield.
1 H NMR d 0.84 (t, 3H, J = 6.6 Hz), 1.05 (br s, 2H), 1.14-1.22 (m, 6H), 1.25 (s, 6H), 1.52-1.57 (m, 2H), 6.60-6.65 (m, 1H), 6.81-6.90 (m, 2H), 7.15 (t, 1H, J = 7.8 Hz).
4-(1,1-Dimethylheptyl)phenol (26)
This was prepared from 24 using BBr 3 /CH 2 Cl 2 in 95% yield by the same procedure as described for 25. 
11-[3-(1,1-Dimethylheptyl)phenoxy]undeca-5,8-dienoic acid methyl ester (27)
To a stirred solution of 25 (2.5 g, 11 mmol) and 16 (1.12 g, 3.8 mmol) in dry DMF (5 mL) was added KOH (0.65 g, 11 mmol). The reaction solution was stirred at 50°C for 3 h and monitored by TLC. The reaction was worked up by diluting with water followed by extraction with EtOAc (5 · 100 mL). The organic extracts were washed with brine, dried and concentrated in vacuo. The brown residue obtained was chromatographed on silica eluting with 5% EtOAc-hexanes to give 0.85 g of 27 as a viscous oil in 53% yield. 1 
11-[3-(1,1-Dimethylheptyl)phenoxy]undeca-5,8-dienoic acid [R(1-hydroxypropan-2-yl)]-amide 1 (O-2220)
LiOH (0.171 g, 0.0042 mol) was added to a solution of 27 (0.25 g, 0.0006 mol) in MeOH (18 mL) and H 2 O (6 mL) and the reaction was left to stir overnight at 50°C. On completion the reaction was cooled to room temperature and the solution acidified to pH 1.0 followed by extraction with ether. The organic extracts were dried and concentrated in vacuo to yield 0.24 g of the corresponding acid as a yellow oil to be used without further purification. 1 
1-o-Tolylheptan-1-one (29)
This was prepared from o-toluic acid in 55% yield by the same procedure as described for 21. (33) A solution of 32 (2.7 g, 0.08 mol) and triphenylphosphine (2.4 g, 0.009 mol) in dry CH 3 CN (50 mL) was refluxed overnight. The solvent was removed in vacuo and the viscous residue was purified by washing and decanting repeatedly with hexanes and benzene until most of the excess triphenylphosphine was removed. The viscous residue was dried in a vacuum oven for 24 h at 50°C to give 4.2 g of 33 as a pale yellow gum in 90% yield. To a stirring THF/HMPA solution (62 mL/8 mL) of 33 (3.78 g, 6.2 mmol) at À30°C, was added NHMDS (6.5 mL, 6.2 mmol, 1 M in THF). The fluorescent red mixture was then allowed to warm to 0°C. After 20 min the mixture was cooled to À78°C and the aldehyde 31 (1.4 g, 6.0 mmol) dissolved in THF (30 mL) was added dropwise. The reaction mixture was warmed to room temperature and refluxed overnight. The mud brown mixture was diluted with hexanes (100 mL) and filtered through a plug of silica. The solvent was removed in vacuo and the residue was chromatographed on silica eluting with 5% EtOAc-hexanes to afford 1.3 g of 34 as a viscous oil in 50% yield. (35) 4-Bromophenoxybutane (10 g, 0.043 mol) and Mg powder (1.4 g, 325 mesh, 0.058 mol) in 500 mL THF was refluxed for 2 h. The reaction mixture was then cooled to room temperature and 3-methoxybenzonitrile (3.54 g, 0.029 mol) was added and again refluxed for 2 h. The imine formed was hydrolyzed with dropwise addition of 6 N HCl (150 mL) to the reaction solution cooled in ice-bath and reaction mixture was then refluxed overnight. The solvent was removed in vacuo and saturated NH 4 Cl solution (600 mL) added. The aqueous layer was extracted with EtOAc (4 · 200 mL), organic extracts were combined, dried and concentrated in vacuo. The residue was purified by column chromatography, eluting with 10% EtOAc-hexanes to yield 8 g of 35 in 64% yield as a white crystalline solid. 
3-(5-Bromo-1,1-dimethylpentyl)phenol (37)
This was prepared from 36 using BBr 3 /CH 2 Cl 2 in 93% yield by the same procedure as described for 25. 
3-(5-Hydroxy-1,1-dimethylpentyl)phenol (38)
A solution of compound 37 (3.36 g, 0.012 mol) in 20% aqueous HMPA solution (70 mL) was stirred overnight at 110°C. The reaction mixture was cooled to room temperature, diluted with water (150 mL) followed by extraction with EtOAc. The organic extracts were combined, dried and concentrated in vacuo. The residue was purified by column chromatography, eluting with 15-40% EtOAc-hexanes. The residue was subjected to column chromatography on silica to afford 1. 
3-[5-(tert-Butyldimethylsilanyloxy
To the phenol 38 (0.11 g, 0.53 mmol) dissolved in DMF (10 mL), was added imidazole (0.09 g, 1.4 mmol) and the reaction solution was cooled to 0°C. To this was added tert-butyldimethylsilyl chloride (0.088 g, 0.53 mmol) and the reaction mixture was stirred for 7 h. The reaction was then diluted with water followed by extraction with EtOAc (4 · 50 mL). The organic extracts were combined, dried and concentrated. The residue was purified by column chromatography, eluting with 5-10% EtOAc-hexanes to give 0.1 g of the desired product 39 in 55% yield. A mixture of compound 40 (0.043 g, 0.083 mmol), NaCN (1 mg, 0.016 mmol) and (R)-2-aminopropan-1-ol (0.06 mL, 0.083 mmol) in methanol (3 mL) was heated for 48 h in a sealed glass vial at 60°C. The reaction progress was monitored by TLC and on completion was evaporated to dryness. The residue was purified by column chromatography, eluting with 50% EtOAc-hexanes and 120 mg of the desired amide derivative was obtained as a colorless oil in 64% yield. 21 mmol) in THF (10 mL), followed by AcOH (0.12 mL, 0.21 mmol) and reaction mixture stirred overnight. On completion, the reaction solution was diluted with water followed by extraction with ether. The organic extracts were combined, dried and concentrated in vacuo. The residue was purified through flash column chromatography on silica and 0.07 g of 4 was obtained as a yellow oil on elution with 2% MeOH-EtOAc in 73% yield. The bromide 43 was obtained in 88% yield from 41 as a colored oil by a procedure similar to that described for 12. The bromide 43 (0.36 g, 0.8 mmol) was dissolved in 8 mL anhydrous DMSO followed by the addition of NaCN (0.14 g, 2.9 mmol) and the reaction progress was monitored by TLC. After 4 h at 50°C, the reaction mixture was diluted with water followed by extraction with EtOAc. The organic extracts were combined, washed with brine, dried and concentrated in vacuo. The residue was purified by flash column and 0. 
The acid was obtained in 96% yield as a colorless oil from 44 by similar procedure as described for acid of 1 except the reaction was performed at room temperature. 1 
Drug preparation and administration
For binding assays, the compounds were prepared as 1 mg/mL stock solutions in absolute ethanol and were stored at À20°C. For behavioral assays, drugs were dissolved in a 1:1:18 mixture of ethanol, emulphor (GAF Corp., Linden, NJ), and saline (0.9% NaCl) and were administered intravenously (iv) in the mouse tail vein in volumes of 0.1 mL/10 g of body weight.
Membrane preparations
HEK-293 cells stably expressing the human CB1 receptor were cultured in DMEM with 10% FBS and Chinese Hamster Ovary (CHO) cells stably expressing the human CB2 receptor were cultured in DMEM with 10% FCS. Cells were harvested by replacement of the media with cold phosphate-buffered saline containing 1 mM EDTA followed by centrifugation at 1000g for 5 min at 4°C. The pellet was resuspended in 50 mM Tris-HCl containing 320 mM sucrose, 2 mM EDTA and 5 mM MgCl 2 (pH 7.4) (centrifugation buffer), then centrifuged at 100g for 10 min at 4°C and the resulting supernatant was saved. This process was repeated twice. The supernatant fractions were combined and centrifuged at 40,000g for 30 min at 4°C. The resulting P2 pellet was resuspended in assay buffer (50 mM TrisHCl (pH 7.4), 3 mM MgCl 2 , 0.2 mM EGTA, and 100 mM NaCl) and protein was measured. Membranes were stored at À80°C until use.
Receptor binding
Membrane homogenates (50 lg) were incubated with 0.5 nM [ 3 H]CP55,940 in the presence of varying concentrations (1 nM-10 lM) of test compounds in 0.5 mL of buffer containing bovine serum albumin (5 mg/mL). Non-specific binding was measured in the presence of 1 mM CP55,940. The assay was incubated at 30°C for 1 h and terminated by addition of ice-cold 50 mM Tris-HCl containing bovine serum albumin (1 mg/mL) (pH 7.4) followed by filtration under vacuum through Whatman GF/B glass fiber filters with three washes with cold Tris buffer. Bound radioactivity was determined by liquid scintillation spectrophotometry at 50% efficiency after extraction by shaking samples for 30-60 min with Budget-Solve scintillation fluid. Data are reported as meanS ± SEM of three experiments, each performed in triplicate. K i values were calculated from displacement data using Equilibrium Binding Data Analysis (BIO-SOFT, Milltown, NJ).
Behavioral evaluations
All mice were acclimated to the laboratory overnight. Each mouse was tested in two of the tetrad assays: locomotor activity and tail flick or rectal temperature and ring immobility. Prior to injection, baseline latency in the tail flick test was measured in mice in the first group. This procedure involved placing the mouse's tail on an ambient heat source (i.e., bright light) and recording latency (in seconds) for tail removal. Typical control latencies were 2-4 s. A 10-s maximal latency was used in order to avoid damage to the mouse's tail. After measurement of baseline tail flick latency, mice were injected iv with vehicle or drug. Four minUTES later they were re-tested in the tail flick procedure. Immediately thereafter, the mice were placed into individual photocell activity cages (11 · 6.5 in.) for assessment of spontaneous activity. For the next 10 min the total number of beam interruptions in the 16 photocell beams/cage was recorded using a Digiscan Animal Activity Monitor (Omnitech Electronics Inc., Columbus, OH). Spontaneous activity was expressed as percent of the control (vehicle) group's activity. Antinociception was expressed as the percent maximum possible effect (MPE) using a 10-s maximum test latency as described earlier. Each dose tested in the antinociception and hypomotility assays represents one group of animals (6 mice/group). Cannabinoid-induced hypothermia and immobility were determined in a separate group of animals. Prior to vehicle or drug administration, rectal temperature was determined by a thermistor probe (inserted 25 mm) and a telethermometer (Yellow Springs Instrument Co., Yellow Springs, OH). Four minutes after the i.v. injection of the drug, body temperature was measured again. The difference between pre-and postinjection rectal temperatures was calculated as change in body temperature. Immediately after measurement of body temperature, the mice were placed on a 5.5-cm ring attached at a height of 16 cm to a ring stand, and the amount of time the animals remained motionless during a 5-min period was recorded. The time that each animal remained motionless on the ring was divided by 300 s and multiplied by 100 to obtain a percent immobility rating.
Data analysis
Based on data obtained from numerous previous in vivo studies with cannabinoids, maximal cannabinoid effects in each in vivo pharmacological procedure were esti-mated as follows: 90% inhibition of spontaneous activity, 100% MPE in the tail flick procedure, and À3°C change in rectal temperature. Means and standard error (S.E.) were calculated for %MPE, number of photocell disruptions, % ring immobility and D°C. Analysis of variance (ANOVA) was used to determine significant differences between control and treatment groups followed by Dunnett's t-test post hoc analysis. Statistical analysis was performed using StatView, version 5.0 (SAS Institute, Cary, NC). Significance was defined as a p < 0.05. ED 50 s were defined as the dose at which half maximal effect occurred. For drugs that produced one or more cannabinoid effect, ED 50 s were calculated separately using least-squares linear regression on the linear part of the dose-effect curve for each measure in the mouse tetrad, plotted against log10 transformation of the dose. For the purposes of potency comparison, ED50s are expressed as lmol/kg.
